4.6 Review

Updated international consensus report on the investigation and management of primary immune thrombocytopenia

期刊

BLOOD ADVANCES
卷 3, 期 22, 页码 3780-3817

出版社

ELSEVIER
DOI: 10.1182/bloodadvances.2019000812

关键词

-

资金

  1. Amgen
  2. Novartis
  3. Rigel

向作者/读者索取更多资源

Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This article is an update of the International Consensus Report published in 2010. A critical review was performed to identify all relevant articles published between 2009 and 2018. An expert panel screened, reviewed, and graded the studies and formulated the updated consensus recommendations based on the new data. The final document provides consensus recommendations on the diagnosis and management of ITP in adults, during pregnancy, and in children, as well as quality-of-life considerations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据